Cost-Utility Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early HER-2 Positive Breast Cancer
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2247
https://www.valueinhealthjournal.com/article/S1098-3015(16)33613-0/fulltext
Title :
Cost-Utility Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early HER-2 Positive Breast Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33613-0&doi=10.1016/j.jval.2016.09.2247
First page :
A739
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2129